Loading clinical trials...
Loading clinical trials...
Pilot Study on Lung Cancer Screening Implementation Among Employees at Lyon Hospital
Several randomized studies have demonstrated the efficiency of lung cancer screening (LCS) on mortality rates. However, screening efficiency is related to the targeted population and the participation rate. In France, the participation rate for breast and colon cancer screening programs is respectively 50% and 32%, which is low. Then, it appears very important to determine which factors are influencing the willingness to participate to these programs. Indeed, it will allow a better communication and we will be able to perform screening campaigns adapted to the eligible population. The Lyon Hospital is the second university hospital in France. It is composed of 14 buildings and employed 23 000 persons. More than 160 occupations are represented. So, hospital employees look relevant to be studied for LCS program. ILYAD was divided in 2 parts. The first one was completed in 2020 and goal to evaluate the number of eligible individuals among the hospital employees. About 800 persons would be eligible for LCS. This second part of the study will evaluate the participation rate and the feasibility of the LCS program. The study will target the 800 individuals that were identified previously.
Age
50 - 75 years
Sex
ALL
Healthy Volunteers
No
Hôpital L. Pradel
Bron, France
Hôpital de la Croix Rousse - Department of Pneumology
Lyon, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Start Date
September 21, 2022
Primary Completion Date
September 12, 2024
Completion Date
September 12, 2024
Last Updated
September 28, 2023
600
ESTIMATED participants
Solicitation for lung cancer screening
BEHAVIORAL
added exams to the usual lung cancer screening
OTHER
Lead Sponsor
Hospices Civils de Lyon
NCT07336732
NCT07486219
NCT05692635
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions